At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 147 enrolled
Drug / intervention
placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of the Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
In Brief
A Phase 2 clinical trial evaluating placebo and A007 for Cervical Intraepithelial Neoplasia and Uterine Cervical Dysplasia. Completed, enrolled 147 participants across 29 sites.
Detailed Summary
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth). The purpose of this study is to evaluate the safety and efficacy of A-007, when used to treat high-grade cervical dysplasia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedFeb 2006
Primary CompletionApr 2008
Study CompletionJun 2008
TodayJul 2026
First PostedFeb 1, 2006
Enrollment StartJan 1, 2006
Primary CompletionApr 1, 2008
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.4 years ago
Interventions
placebodrug
5 days of 28 day cycle for 2 cycles
A007drug
5 days of 28 day cycle